Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: protocol

Andre Rodrigues Duraes, Pollianna Ds Roriz, Fabio V Bulhoes, Bianca DA Nunes, Juliana Qv Muniz, Italvar Ndcr Neto, Andre Ms Fernandes, Francisco Jfbd Reis, Edmundo Jn Camara, Erenaldo Dsr Junior, Deusdeth Ts Segundo, Felipe Pinho E Albuquerque Silva, Roque Aras, Andre Rodrigues Duraes, Pollianna Ds Roriz, Fabio V Bulhoes, Bianca DA Nunes, Juliana Qv Muniz, Italvar Ndcr Neto, Andre Ms Fernandes, Francisco Jfbd Reis, Edmundo Jn Camara, Erenaldo Dsr Junior, Deusdeth Ts Segundo, Felipe Pinho E Albuquerque Silva, Roque Aras

Abstract

Background: Warfarin and similar vitamin K antagonists have been the standard therapy for patients with mechanical or biological valve prosthesis and atrial fibrillation (AF). Even with the appropriate use of therapy, some studies have reported that there is a high incidence of thromboembolic events, 1%-4% per year. Furthermore, a bleeding risk is significant, ranging from 2% to 9% per year, according to some studies.

Objective: The objective of our study was to examine the effect of dabigatran etexilate versus dose-adjusted warfarin for the prevention of intracardiac thrombus in persistent or permanent AF at least 3 months after aortic and/or mitral bioprosthesis replacement.

Methods: Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively (DAWA) is a phase 2, prospective, open label, randomized exploratory pilot study. The main variable to be observed in this study is intracardiac thrombus. From August 2013 to April 2015, 100 patients, at least 3 months after aortic and/or mitral bioprosthesis replacement and permanent or persistent AF postoperatively, who match eligibility criteria will be selected from Ana Nery Hospital in Salvador-Bahia with a follow-up of three months. Patients were randomly assigned in a 1:1 ratio to receive either dabigatran etexilate or warfarin.

Results: Although the present study has no statistic power to proof non-inferiority, it is expected that the dabigatran etexilate group will be protected as well as the warfarin group from intracardiac thrombus, without increasing the bleeding rates, since we are using safer doses (110 mg bid). The lack of necessity of monitoring INR is also another factor that contributes to a better adherence to the new drug and it can make all the difference in the manner of doing anticoagulation for patients with similar clinical characteristics.

Conclusions: The study is in the recruitment phase. It is possible that dabigatran etexilate is as effective as warfarin in preventing the emergence of intracardiac thrombus in patients with AF and mitral and/or aortic bioprosthesis.

Trial registration: Clinicaltrials.gov NCT01868243; https://ichgcp.net/clinical-trials-registry/NCT01868243 (Archived by WebCite at http://www.webcitation/6OABiuasd).

Keywords: anticoagulants; atrial fibrillation; dabigatran; hematologic agents; stroke; warfarin.

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
DAWA study.

References

    1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005 Nov;5(11):685–694. doi: 10.1016/S1473-3099(05)70267-X.
    1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: A population-based study. Lancet. 2006 Sep 16;368(9540):1005–1011. doi: 10.1016/S0140-6736(06)69208-8.
    1. Sun JC, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: Current evidence and future trends. Lancet. 2009 Aug 15;374(9689):565–576. doi: 10.1016/S0140-6736(09)60780-7.
    1. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994 Feb;89(2):635–641.
    1. Cortelazzo S, Finazzi G, Viero P, Galli M, Remuzzi A, Parenzan L, Barbui T. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost. 1993 Apr 1;69(4):316–320.
    1. Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med. 2000 Oct 15;109(6):481–488.
    1. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009 May;157(5):805–810. doi: 10.1016/j.ahj.2009.02.005.
    1. O'Dell KM, Igawa D, Hsin J. New oral anticoagulants for atrial fibrillation: A review of clinical trials. Clin Ther. 2012 Apr;34(4):894–901. doi: 10.1016/j.clinthera.2012.01.019.
    1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–1151. doi: 10.1056/NEJMoa0905561.
    1. Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation. 2013 Jul 16;128(3):237–243. doi: 10.1161/CIRCULATIONAHA.112.001139.
    1. U.S. Department of Health and Human Services. [2014-03-09]. FDA drug safety communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves .
    1. Haahr M. . [2014-03-09]. List randomizer
    1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest. 2008 Jun;133(6 Suppl):160S–198S. doi: 10.1378/chest.08-0670.
    1. Tran HA, Chunilal SD, Harper PL, Tran H, Wood EM, Gallus AS, Australasian Society of Thrombosis and Haemostasis (ASTH) An update of consensus guidelines for warfarin reversal. Med J Aust. 2013 Mar 4;198(4):198–199.
    1. Peacock WF, Gearhart MM, Mills RM. Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol. 2012 Dec;35(12):730–737. doi: 10.1002/clc.22037.
    1. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH, American College of Chest Physicians Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e576S–600S. doi: 10.1378/chest.11-2305.
    1. Wittkowsky AK, Spinler SA, Dager W, Gulseth MP, Nutescu EA. Dosing guidelines, not protocols, for managing warfarin therapy. Am J Health Syst Pharm. 2010 Sep 15;67(18):1554–1556. doi: 10.2146/ajhp100064.
    1. Becattini C, Vedovati MC, Agnelli G. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature. Thromb Res. 2012 Mar;129(3):392–400. doi: 10.1016/j.thromres.2011.12.014.
    1. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692–694. doi: 10.1111/j.1538-7836.2005.01204.x.
    1. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F, RE-ALIGN Investigators Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep 26;369(13):1206–1214. doi: 10.1056/NEJMoa1300615.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever